CalciMedica (CALC)
NASDAQ:CALC
Want to see CALC full AI Analyst Report?
Top Page
CalciMedica
(NASDAQ:CALC)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.74
▲(22.67% Upside)
Action:Reiterated
Date:06/09/26
The score is primarily pressured by weak financial fundamentals (no revenue, ongoing losses, heavy cash burn, and negative equity) and heightened listing-risk from Nasdaq deficiency notices. Technical indicators show some near-term momentum improvement, but longer-term trend measures remain weak, and valuation signals are limited due to negative earnings and no dividend.
Positive Factors
Targeted clinical-stage pipeline
CalciMedica's focused development of Auxora, a CRAC channel inhibitor targeting acute inflammatory and immunologic conditions, represents a clear, durable scientific strategy. A differentiated mechanism can create a sustainable competitive edge in niche high-unmet-need indications if clinical validation is achieved, concentrating R&D and partner interest over multiple quarters.
Negative Factors
Pre-revenue with heavy cash burn
With no product revenue and persistent operating and free cash flow burn near -$21M TTM, CalciMedica remains structurally dependent on external financing to fund development. This funding dependency increases dilution risk, creates execution pressure on clinical milestones, and makes the company vulnerable to tighter capital markets over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted clinical-stage pipeline
CalciMedica's focused development of Auxora, a CRAC channel inhibitor targeting acute inflammatory and immunologic conditions, represents a clear, durable scientific strategy. A differentiated mechanism can create a sustainable competitive edge in niche high-unmet-need indications if clinical validation is achieved, concentrating R&D and partner interest over multiple quarters.
Read all positive factors
CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.93M
Dividend YieldN/A
Average Volume (3M)71.94K
Price to Earnings (P/E)―
Beta (1Y)-0.24
Revenue GrowthN/A
EPS Growth16.33%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.33
Shares Outstanding15,798,031
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-729.48
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$10.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
CalciMedica Business Overview & Revenue Model
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approac...
How the Company Makes Money
null...
CalciMedica Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | -519.00K |
| EBITDA | -18.21M | -28.09M | -13.64M | -34.19M | -7.64M | -35.30M |
| Net Income | -19.54M | -29.56M | -13.70M | -34.36M | -7.82M | -35.82M |
Balance Sheet | ||||||
| Total Assets | 8.61M | 13.59M | 19.79M | 12.19M | 3.35M | 69.09M |
| Cash, Cash Equivalents and Short-Term Investments | 8.16M | 13.02M | 18.67M | 11.24M | 1.33M | 63.67M |
| Total Debt | 0.00 | 9.70M | 0.00 | 0.00 | 5.36M | 0.00 |
| Total Liabilities | 9.71M | 20.23M | 5.38M | 4.03M | 12.58M | 4.07M |
| Stockholders Equity | -1.10M | -6.64M | 14.41M | 8.16M | -9.23M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -21.18M | -21.21M | -21.15M | -25.81M | -11.76M | -31.99M |
| Operating Cash Flow | -21.16M | -21.18M | -21.15M | -25.73M | -11.76M | -31.50M |
| Investing Cash Flow | 12.29M | 9.55M | -4.42M | 8.88M | -4.00K | 10.75M |
| Financing Cash Flow | 4.47M | 15.21M | 27.97M | 20.90M | 8.48M | 695.00K |
CalciMedica Technical Analysis
Negative
0.60
Price Trends
0.70
Positive
0.73
Positive
2.38
Negative
Market Momentum
0.04
Positive
46.02
Neutral
11.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 0.70, and below the 200-day MA of 2.38, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 11.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CALC.
CalciMedica Risk Analysis
CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CalciMedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $48.36M | -2.68 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $53.30M | -1.59 | -346.03% | ― | ― | 28.53% | |
49 Neutral | $29.02M | -0.56 | -503.79% | ― | ― | 82.28% | |
45 Neutral | $11.93M | -0.58 | -526.36% | ― | ― | 16.33% | |
41 Neutral | $24.86M | -0.49 | -217.27% | ― | ― | -74.39% |
* Healthcare Sector Average
CALC
CalciMedica
0.76
-0.79
-50.97%
PDSB
PDS Biotechnology
0.96
-0.59
-37.99%
SKYE
Skye Bioscience
0.71
-2.16
-75.37%
LTRN
Lantern Pharma
3.79
0.72
23.45%
SNTI
Senti Biosciences
0.93
-1.06
-53.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.